Adverse Reaction Reporting. (a) Alcon shall advise Pharmacyclics, by telephone or facsimile, within such time as is required by the FDA or foreign equivalent (with respect to the severity and/or increased frequency of such adverse reaction) after it becomes aware of any adverse reaction to the use of the Licensed Product developed, marketed or sold by Alcon. Alcon shall provide Pharmacyclics with a written report delivered by confirmed facsimile of any reported adverse reaction, stating
Appears in 3 contracts
Sources: Evaluation and License Agreement (Pharmacyclics Inc), Evaluation and License Agreement (Pharmacyclics Inc), Evaluation and License Agreement (Pharmacyclics Inc)